1
/
of
1
Letero (Letrozole)
Letero (Letrozole)
Regular price
₱4,205.00 PHP
Regular price
Sale price
₱4,205.00 PHP
Unit price
₱140.17 each
Taxes included.
Quantity
Couldn't load pickup availability
Letrozole (Letero) – Non-Steroidal Aromatase Inhibitor for Hormone Receptor–Positive Breast Cancer Treatment
Letrozole is a non-steroidal aromatase inhibitor specifically designed for the treatment of hormone receptor–positive breast cancer in postmenopausal women. This prescription medication works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens in the body. By inhibiting this conversion process, letrozole effectively reduces circulating estrogen levels, thereby suppressing the growth and proliferation of estrogen-dependent breast cancer cells.
Clinical Applications and Therapeutic Uses
Letrozole serves multiple roles in breast cancer management across different treatment phases. As a first-line treatment option, it is indicated for postmenopausal women diagnosed with advanced or metastatic hormone receptor–positive breast cancer. In the adjuvant setting, letrozole is prescribed for early-stage breast cancer patients to reduce the risk of cancer recurrence and improve long-term survival outcomes. Additionally, letrozole may be used as extended adjuvant therapy following previous tamoxifen treatment, providing continued hormonal suppression during the extended treatment phase. Off-label applications include use in fertility treatment protocols, where letrozole may induce ovulation in women with polycystic ovary syndrome (PCOS) under specialized medical supervision.
Important Contraindications and Patient Restrictions
Letrozole is contraindicated in premenopausal women, except when used off-label under established fertility treatment protocols. Pregnancy is an absolute contraindication due to its FDA Category X classification, which indicates potential for serious fetal harm. Breastfeeding mothers should not use letrozole, as the drug may pass into breast milk and harm nursing infants. Patients with known hypersensitivity or allergic reactions to letrozole or any formulation component should not use this medication.
Dosage and Medical Guidance
The appropriate dosage of letrozole varies based on individual patient factors, cancer type, and treatment goals. Dosing must be determined and prescribed by a qualified healthcare provider following comprehensive medical evaluation. This medication requires strict medical supervision and should never be initiated without proper consultation with a physician.
Precautions and Safety Considerations
Before beginning letrozole therapy, patients must undergo thorough medical evaluation to ensure suitability for treatment. Regular monitoring and follow-up appointments with healthcare providers are essential during treatment. Patients should immediately report any adverse effects or concerns to their physician. This medication should only be used under direct medical supervision and according to prescribed instructions.
Letrozole is a non-steroidal aromatase inhibitor specifically designed for the treatment of hormone receptor–positive breast cancer in postmenopausal women. This prescription medication works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens in the body. By inhibiting this conversion process, letrozole effectively reduces circulating estrogen levels, thereby suppressing the growth and proliferation of estrogen-dependent breast cancer cells.
Clinical Applications and Therapeutic Uses
Letrozole serves multiple roles in breast cancer management across different treatment phases. As a first-line treatment option, it is indicated for postmenopausal women diagnosed with advanced or metastatic hormone receptor–positive breast cancer. In the adjuvant setting, letrozole is prescribed for early-stage breast cancer patients to reduce the risk of cancer recurrence and improve long-term survival outcomes. Additionally, letrozole may be used as extended adjuvant therapy following previous tamoxifen treatment, providing continued hormonal suppression during the extended treatment phase. Off-label applications include use in fertility treatment protocols, where letrozole may induce ovulation in women with polycystic ovary syndrome (PCOS) under specialized medical supervision.
Important Contraindications and Patient Restrictions
Letrozole is contraindicated in premenopausal women, except when used off-label under established fertility treatment protocols. Pregnancy is an absolute contraindication due to its FDA Category X classification, which indicates potential for serious fetal harm. Breastfeeding mothers should not use letrozole, as the drug may pass into breast milk and harm nursing infants. Patients with known hypersensitivity or allergic reactions to letrozole or any formulation component should not use this medication.
Dosage and Medical Guidance
The appropriate dosage of letrozole varies based on individual patient factors, cancer type, and treatment goals. Dosing must be determined and prescribed by a qualified healthcare provider following comprehensive medical evaluation. This medication requires strict medical supervision and should never be initiated without proper consultation with a physician.
Precautions and Safety Considerations
Before beginning letrozole therapy, patients must undergo thorough medical evaluation to ensure suitability for treatment. Regular monitoring and follow-up appointments with healthcare providers are essential during treatment. Patients should immediately report any adverse effects or concerns to their physician. This medication should only be used under direct medical supervision and according to prescribed instructions.
Share
